glp-1 obesity drug market news today Market: the rapid growth of the diabetes and drugs Glp-1 Analogues Market Size, Share

Description

51.Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial

Novo Nordisk spent approximately $6.3 billion on production investments in 2023 and increased that figure to approximately $6.8 billion in 2024

The following is from p S66 of Resource (2) The following text is from pp S66 + 67, S70 of Resource (2) Combination Therapy Although there are numerous trials comparing dual therapy with metformin alone, few directly compare drugs as add-on therapy

Clinical Evidence We currently have very limited evidence in support of the use of GLP-1 or dual GIP/GLP-1 medications in treating adults with type 1 diabetes

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial